Full Press Release Details
Medical Initiates Search for U.S. Clinical Sites for the LIBERTY Robotic System
Mass., December 22, 2021 - Microbot Medical Inc. (Nasdaq: MBOT) announced that it has and will continue to implement key initiatives
that will prepare the LIBERTY Robotic System for commercialization. In conjunction with recently announced design freeze, Dr. Eyal
Morag, Microbot's Chief Medical Officer, traveled to the United States to establish a clinical infrastructure with multiple sites
and leading physicians for the commencement of a human clinical trial, which is expected to commence in the second half of 2022.
actions reflect an inflection point in LIBERTY's developmental pathway and it is critical that we align our interests to ensure
we successfully execute the value-enhancing catalysts in 2022, including the FDA pre-submission and the human clinical trial expected
in the second half of 2022," commented Dr. Eyal Morag, Microbot's Chief Medical Officer. "My primary goal over the
next few months is to leverage our resources and to educate the market on the clinical and economic benefits of the LIBERTY Robotic System
to ensure future success in commercialization."
Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies,
focused primarily on both natural and artificial lumens within the human body. Microbot's current proprietary technological platforms
provide the foundation for the development of a Multi Generation Pipeline Portfolio (MGPP).
Medical was founded in 2010 by Harel Gadot, Prof. Moshe Shoham, and Yossi Bornstein with the goals of improving clinical outcomes for
patients and increasing accessibility through the use of micro-robotic technologies. Further information about Microbot Medical is available
pertaining to the registered direct offering, timing, the amount and anticipated use of proceeds and statements pertaining to future
financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for Microbot
Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed
by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the
Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such
as "will," "believes," "plans," "anticipates," "expects" and "estimates")
should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without
limitation, market conditions and the satisfaction of customary closing conditions, risks inherent in the development and/or commercialization
of potential products, including LIBERTYTM and SCS, the outcome of its studies to evaluate LIBERTY, SCS and other existing
and future technologies, uncertainty in the results of pre-clinical and clinical trials or regulatory pathways and regulatory approvals,
uncertainty resulting from the COVID-19 pandemic, need and ability to obtain future capital, and maintenance of intellectual property
rights. Additional information on risks facing Microbot Medical can be found under the heading "Risk Factors" in Microbot
Medical's periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC's web
site at www.sec.gov. Microbot Medical disclaims any intent or obligation to update these forward-looking statements, except as required